Daxor Corporation logo

Daxor Corporation (DXR)

Market Open
15 Jun, 13:30
NASDAQ (CM) NASDAQ (CM)
$
9. 90
+0.64
+6.9114%
$
46.66M Market Cap
68.22 P/E Ratio
- Div Yield
1,264 Volume
0 Eps
$ 9.26
Previous Close
Add Transaction
Day Range
9.87 9.9
Year Range
8.45 14.76
Want to track DXR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

DXR trading today higher at $9.9, an increase of 6.9114% from yesterday's close, completing a monthly decrease of -10% or -$1.1. Over the past 12 months, DXR stock lost -32.8814%.
DXR pays dividends to its shareholders, with the most recent payment made on Jan 12, 2018. The next estimated payment will be in 12 Jan 2019 on Jan 12, 2019 for a total of $0.03.
The last earnings report, released on Mar 04, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0233%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

DXR Chart

People also search for

Viewbix Inc.
$ 4.8
+3.5599%
Sharps Technology Inc.
$ 1.25
+11.1607%
Exyn Technologies, Inc.
$ 6.2
+4.7297%
Precision Optics Corporation, Inc.
$ 6.04
+2.5467%
SuperCom Ltd.
$ 9.93
+0.6454%
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Seekingalpha | 3 months ago
Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript

Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript

Daxor Corporation (NASDAQ:DXR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024.

Seekingalpha | 1 year ago

Daxor Corporation (DXR) FAQ

What is the stock price today?

The current price is $9.90.

On which exchange is it traded?

Daxor Corporation is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is DXR.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 46.66M.

Has Daxor Corporation ever had a stock split?

No, there has never been a stock split.

Daxor Corporation Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Michael Richard Feldschuh CEO
NASDAQ (CM) Exchange
239467103 CUSIP
US Country
37 Employees
12 Jan 2018 Last Dividend
- Last Split
17 Mar 1992 IPO Date

Overview

Daxor Corporation is an innovative medical device company specializing in the advancement of blood volume measurement technology. Pivotal to its operations is the focus on developing and providing a diagnostic blood test known as BVA-100 Blood Volume Analyzer. This proprietary technology is centered around delivering safe, accurate, and objective quantification of a patient's blood volume status and composition, benchmarked against patient-specific norms. The ability to precisely determine blood volume is critical across a myriad of medical and surgical conditions, thereby underscoring the importance of Daxor's contributions to the healthcare sector. Originally established as Idant Corporation, the company underwent a rebranding to Daxor Corporation in May 1973, marking a significant milestone in its corporate evolution. With its roots tracing back to 1971, Daxor Corporation is strategically headquartered in Oak Ridge, Tennessee, from where it continues to innovate and impact the medical community.

Products and Services

  • BVA-100 Blood Volume Analyzer
  • Daxor's flagship product, the BVA-100 Blood Volume Analyzer, represents a groundbreaking approach to blood volume analysis. This diagnostic tool is engineered to provide an accurate and objective measurement of a patient's blood volume status and composition relative to individual-specific norms. The technology's precision and safety make it an invaluable resource for clinicians across various medical and surgical specialties seeking to diagnose and manage conditions related to blood volume imbalances.

Contact Information

Address: 109 Meco Lane
Phone: 12123308500